Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
3.120
-0.300 (-8.77%)
At close: Dec 5, 2025, 4:00 PM EST
3.200
+0.080 (2.56%)
After-hours: Dec 5, 2025, 7:56 PM EST
Company Description
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer.
Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study.
Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Tempest Therapeutics, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Stephen Brady |
Contact Details
Address: 2000 Sierra Point Parkway, Suite 400 Brisbane, California 94005 United States | |
| Phone | 415 798 8589 |
| Website | tempesttx.com |
Stock Details
| Ticker Symbol | TPST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001544227 |
| CUSIP Number | 87978U207 |
| ISIN Number | US87978U2078 |
| Employer ID | 45-1472564 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen R. Brady J.D., LLM | Chief Executive Officer, President and Director |
| Nicholas Maestas | Chief Financial Officer, Head of Corporate Strategy and Secretary |
| Dr. Samuel Whiting M.D., Ph.D. | Executive Vice President, Chief Medical Officer and Head of Research & Development |
| Justin Trojanowski CPA | Corporate Controller, Treasurer and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2025 | PRE 14A | Other preliminary proxy statements |
| Nov 26, 2025 | 8-K | Current Report |
| Nov 25, 2025 | 424B5 | Filing |
| Nov 19, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 19, 2025 | 8-K | Current Report |
| Nov 5, 2025 | 10-Q | Quarterly Report |
| Nov 5, 2025 | 8-K | Current Report |
| Aug 13, 2025 | SCHEDULE 13D/A | Filing |
| Aug 11, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | 8-K | Current Report |